Profound Medical Corp.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
PROF$7.68+4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended September 30, · · Nine Months Ended September 30, | ||||||||
| | 2025 | 2024 | 2025 | 2024 | ||||
| | | $ | | $ | | $ | | $ |
| Revenue (note 11) | | | | | | | | |
| Recurring - non-capital | 4,066 | 2,653 | | 7,428 | | 5,552 | ||
| Capital equipment | 1,223 | 179 | | 2,693 | | 952 | ||
| | 5,289 | 2,832 | | 10,121 | | 6,504 | ||
| Cost of sales | 1,358 | 1,044 | | 2,719 | | 2,429 | ||
| Gross profit | 3,931 | 1,788 | | 7,402 | | 4,075 | ||
| | | | | | | | | |
| Operating expenses | | | | | | | ||
| Research and development | 5,418 | 4,166 | | 16,324 | | 12,316 | ||
| Selling, general and administrative | 7,426 | 6,620 | | 24,963 | | 16,476 | ||
| Total operating expenses | 12,844 | 10,786 | | 41,287 | | 28,792 | ||
| | | | | | | | | |
| Operating loss | 8,913 | 8,998 | | 33,885 | | 24,717 | ||
| | | | | | | | | |
| Other (income) expenses | | | | | | | ||
| Net finance (income) expense | (122) | (220) | | (910) | | (1,104) | ||
| Net foreign exchange (gain) loss | (935) | 410 | | 1,194 | | (980) | ||
| Total other (income) expenses | (1,057) | 190 | | 284 | | (2,084) | ||
| | | | | | | | | |
| Net loss before income taxes | 7,856 | 9,188 | | 34,169 | | 22,633 | ||
| | | | | | | | | |
| Income tax expense | 100 | 177 | | 219 | | 236 | ||
| Deferred tax expense | 21 | — | | 7 | | — | ||
| Total income tax expense | | 121 | | 177 | | 226 | | 236 |
| | | | | | | | | |
| Net loss attributed to shareholders for the period | 7,977 | 9,365 | | 34,395 | | 22,869 | ||
| | | | | | | | | |
| Other comprehensive (income) loss | | | | | | | ||
| Item that may be reclassified to (income) loss | | | | | | | ||
| Foreign currency translation adjustment | 808 | (584) | | (2,008) | | 855 | ||
| | | | | | | | | |
| Net loss and other comprehensive loss for the period | 8,785 | 8,781 | | 32,387 | | 23,724 | ||
| | | | | | | | | |
| Loss per share (note 12) | | | | | | | ||
| Basic and diluted net loss per common share | 0.26 | 0.38 | | 1.14 | | 0.94 | ||
| Basic and diluted weighted average common shares outstanding | 30,104,497 | 24,534,964 | | 30,119,569 | | 24,427,960 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.